Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Medipal’s Subsidiary to Distribute Stemirac in Japan
Medipal Holdings said on April 8 that its subsidiary SPLine and Nipro entered into a distribution agreement for Nipro’s stem cell therapy Stemirac for spinal cord injury (SCI) in Japan during its conditional, time-limited approval period. With Stemirac, mesenchymal stem…
To read the full story
Related Article
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
- Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
BUSINESS
- DNP, CMIC, NEXEL Form JV to Take iPSC-Based Drug Testing Global
October 13, 2026
- Asahi Kasei Therapeutics Doses First Patient in AIC468 PIIa Trial
October 13, 2026
- Kissei Group Firm Hit by Cyberattack, Personal Data at Risk
October 13, 2026
- Toho Drops PHC Buyout Bid, Still Exploring Growth Options
October 13, 2026
- Sanwa Kagaku on Track to Resume Kumamoto Production in October
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…